Literature DB >> 20955968

Primary sclerosing cholangitis.

Tom H Karlsen1, Erik Schrumpf, Kirsten Muri Boberg.   

Abstract

Primary sclerosing cholangitis (PSC) is a chronic bile duct disease leading to fibrotic biliary strictures and liver cirrhosis. The patient population is heterogeneous with regard to disease progression and the presence of co-morbidities, complicating the practical handling of patients as well as studies of pathogenetic mechanisms. The aetiology of PSC is unknown, but the recent findings of several robust susceptibility genes emphasise the importance of genetic risk factors. There is no effective medical treatment available to delay the disease progression, but endoscopic therapy of biliary stenoses may be indicated. Follow-up of patients includes management of the inflammatory bowel disease that is found in the majority of cases along with investigations aimed at the early detection of cholangiocarcinoma and colorectal cancer, which also occur at increased frequencies. In the present review, we aim to summarise the present knowledge of PSC with a particular emphasis on the possible basis of disease variability.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20955968     DOI: 10.1016/j.bpg.2010.07.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  17 in total

Review 1.  [Liver transplantation for hilar cholangiocarcinoma].

Authors:  F Rauchfuss; F Utess; S Schüle; Y Dittmar; H Scheuerlein; U Settmacher
Journal:  Chirurg       Date:  2012-03       Impact factor: 0.955

2.  High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.

Authors:  M H Imam; E Sinakos; A A Gossard; K V Kowdley; V A C Luketic; M Edwyn Harrison; T McCashland; A S Befeler; D Harnois; R Jorgensen; J Petz; J Keach; A C DeCook; F Enders; K D Lindor
Journal:  Aliment Pharmacol Ther       Date:  2011-09-29       Impact factor: 8.171

Review 3.  Genome-wide association studies and genetic risk assessment of liver diseases.

Authors:  Marcin Krawczyk; Roman Müllenbach; Susanne N Weber; Vincent Zimmer; Frank Lammert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

Review 4.  Metal, magnet or transplant: options in primary sclerosing cholangitis with stricture.

Authors:  Jawad Ahmad
Journal:  Hepatol Int       Date:  2018-11-14       Impact factor: 6.047

Review 5.  TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis?

Authors:  Verena Keitel; Maria Reich; Dieter Häussinger
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

6.  Duct-to-duct biliary reconstruction in patients with primary sclerosing cholangitis undergoing liver transplantation.

Authors:  Jamak Modaresi Esfeh; Bijan Eghtesad; Peter Hodgkinson; Teresa Diago; Masato Fujiki; Koji Hashimoto; Cristiano Quintini; Federico Aucejo; Dympna Kelly; Charles Winans; David Vogt; Charles Miller; Nizar Zein; John Fung
Journal:  HPB (Oxford)       Date:  2011-07-19       Impact factor: 3.647

Review 7.  The genetics of complex cholestatic disorders.

Authors:  Gideon M Hirschfield; Roger W Chapman; Tom H Karlsen; Frank Lammert; Konstantinos N Lazaridis; Andrew L Mason
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

8.  Epithelial markers of colorectal carcinogenesis in ulcerative colitis and primary sclerosing cholangitis.

Authors:  Pavel Wohl; Tomas Hucl; Pavel Drastich; David Kamenar; Julius Spicak; Eva Honsova; Eva Sticova; Alena Lodererova; Jan Matous; Martin Hill; Petr Wohl; Milos Kucera
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

9.  Glycochenodeoxycholic Acid Does Not Increase Transforming Growth Factor-Beta Expression in Bile Duct Epithelial Cells or Collagen Synthesis in Myofibroblasts.

Authors:  Anna Wang; Dorothy Yu; Yuewen Gong; Jessie Garber; Gerald Y Minuk
Journal:  J Clin Exp Hepatol       Date:  2017-05-13

10.  Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.

Authors:  Peter Fickert; Marion J Pollheimer; Dagmar Silbert; Tarek Moustafa; Emina Halilbasic; Elisabeth Krones; Franziska Durchschein; Andrea Thüringer; Gernot Zollner; Helmut Denk; Michael Trauner
Journal:  J Hepatol       Date:  2013-01-29       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.